{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:08:27Z","timestamp":1793916507447,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["U01 AG006786"],"award-info":[{"award-number":["U01 AG006786"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R37 AG011378"],"award-info":[{"award-number":["R37 AG011378"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["P30 AG062677"],"award-info":[{"award-number":["P30 AG062677"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG041851"],"award-info":[{"award-number":["R01 AG041851"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG034676"],"award-info":[{"award-number":["R01 AG034676"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS097495"],"award-info":[{"award-number":["R01 NS097495"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1038\/s41591-022-01822-2","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T16:04:49Z","timestamp":1653581089000},"page":"1398-1405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":420,"title":["Performance of plasma phosphorylated tau 181 and 217 in the community"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7177-1185","authenticated-orcid":false,"given":"Michelle M.","family":"Mielke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2192-1699","authenticated-orcid":false,"given":"Jeffrey L.","family":"Dage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Algeciras-Schimnich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-066X","authenticated-orcid":false,"given":"David S.","family":"Knopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-1016","authenticated-orcid":false,"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4286-0589","authenticated-orcid":false,"given":"Prashanthi","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Graff-Radford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-622X","authenticated-orcid":false,"suffix":"Jr","given":"Clifford R.","family":"Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"1822_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989\u2013997 (2018).","journal-title":"Alzheimers Dement."},{"key":"1822_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"1822_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"1822_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397 (2020).","journal-title":"Nat. Med."},{"key":"1822_CR5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"1822_CR6","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren, N. et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143, 3234\u20133241 (2020).","journal-title":"Brain"},{"key":"1822_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso, A. et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain 144, 325\u2013339 (2021).","journal-title":"Brain"},{"key":"1822_CR8","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, e20200861 (2020).","journal-title":"J. Exp. Med."},{"key":"1822_CR9","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp-2020-323487","volume":"91","author":"A Benussi","year":"2020","unstructured":"Benussi, A. et al. Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J. Neurol. Neurosurg. Psychiatry 91, 960\u2013967 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1822_CR10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simr\u00e9n","year":"2021","unstructured":"Simr\u00e9n, J. et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 17, 1145\u20131156 (2021).","journal-title":"Alzheimers Dement."},{"key":"1822_CR11","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke, M. M. et al. Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol. 78, 1108\u20131117 (2021).","journal-title":"JAMA Neurol."},{"key":"1822_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O\u2019Bryant","year":"2017","unstructured":"O\u2019Bryant, S. E. et al. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimers Dement. 13, 45\u201358 (2017).","journal-title":"Alzheimers Dement."},{"key":"1822_CR13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"1822_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1373\/jalm.2019.030023","volume":"5","author":"MM Mielke","year":"2020","unstructured":"Mielke, M. M. Consideration of sex differences in the measurement and interpretation of Alzheimer disease-related biofluid-based biomarkers. J. Appl. Lab. Med. 5, 158\u2013169 (2020).","journal-title":"J. Appl. Lab. Med."},{"key":"1822_CR15","doi-asserted-by":"publisher","unstructured":"Syrjanen, J. A. et al. Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12466 (online ahead of print).","DOI":"10.1002\/alz.12466"},{"key":"1822_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr.","year":"2017","unstructured":"Jack, C. R.Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"1822_CR17","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jalz.2019.09.079","volume":"16","author":"VJ Lowe","year":"2020","unstructured":"Lowe, V. J. et al. Tau-positron emission tomography correlates with neuropathology findings. Alzheimers Dement. 16, 561\u2013571 (2020).","journal-title":"Alzheimers Dement."},{"key":"1822_CR18","doi-asserted-by":"publisher","first-page":"e14398","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele, R. et al. Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol. Med. 13, e14398 (2021).","journal-title":"EMBO Mol. Med."},{"key":"1822_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman, A. M. et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 17, 1353\u20131364 (2021).","journal-title":"Alzheimers Dement."},{"key":"1822_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.11613\/BM.2016.001","volume":"26","author":"Y Ozarda","year":"2016","unstructured":"Ozarda, Y. Reference intervals: current status, recent developments and future considerations. Biochem. Med. (Zagreb) 26, 5\u201316 (2016).","journal-title":"Biochem. Med. (Zagreb)"},{"key":"1822_CR21","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1001\/jama.2018.2009","volume":"319","author":"AK Manrai","year":"2018","unstructured":"Manrai, A. K., Patel, C. J. & Ioannidis, J. P. A. In the era of precision medicine and big data, who is normal? JAMA 319, 1981\u20131982 (2018).","journal-title":"JAMA"},{"key":"1822_CR22","doi-asserted-by":"publisher","first-page":"8683","DOI":"10.3390\/ijerph18168683","volume":"18","author":"T Yoshihara","year":"2021","unstructured":"Yoshihara, T. et al. Cerebrospinal fluid protein concentration in healthy older Japanese volunteers. Int. J. Environ. Res. Public Health 18, 8683 (2021).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"1822_CR23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739\u2013752 (2021).","journal-title":"Lancet Neurol."},{"key":"1822_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000115751","volume":"30","author":"RO Roberts","year":"2008","unstructured":"Roberts, R. O. et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 30, 58\u201369 (2008).","journal-title":"Neuroepidemiology"},{"key":"1822_CR25","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1093\/ije\/dys195","volume":"41","author":"JL St Sauver","year":"2012","unstructured":"St Sauver, J. L. et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int. J. Epidemiol. 41, 1614\u20131624 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"1822_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40, 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"key":"1822_CR27","doi-asserted-by":"crossref","unstructured":"Beck, A. T., Steer, R. A. & Brown, G. K. Manual for the Beck Depression Inventory-II (Psychological Corporation, 1996).","DOI":"10.1037\/t00742-000"},{"key":"1822_CR28","unstructured":"Beck, A. T. & Steer, R. A. Beck Anxiety Inventory Manual (Psychological Corporation, 1993)."},{"key":"1822_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/13854049208401880","volume":"6","author":"RJ Ivnik","year":"1992","unstructured":"Ivnik, R. J. et al. Mayo\u2019s Older Americans Normative Studies: updated AVLT norms for ages 56 to 97. Clin. Neuropsychol. 6, 83\u2013104 (1992).","journal-title":"Clin. Neuropsychol."},{"key":"1822_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen, R. C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183\u2013194 (2004).","journal-title":"J. Intern. Med."},{"key":"1822_CR31","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (American Psychiatric Association, 1994)."},{"key":"1822_CR32","doi-asserted-by":"publisher","first-page":"878","DOI":"10.2967\/jnumed.108.058529","volume":"50","author":"VJ Lowe","year":"2009","unstructured":"Lowe, V. J. et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 50, 878\u2013886 (2009).","journal-title":"J. Nucl. Med."},{"key":"1822_CR33","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","volume":"25","author":"JC Price","year":"2005","unstructured":"Price, J. C. et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow. Metab. 25, 1528\u20131547 (2005).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"1822_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2967\/jnumed.108.057612","volume":"50","author":"RL McNamee","year":"2009","unstructured":"McNamee, R. L. et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J. Nucl. Med. 50, 348\u2013355 (2009).","journal-title":"J. Nucl. Med."},{"key":"1822_CR35","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/brain\/awm336","volume":"131","author":"CR Jack Jr.","year":"2008","unstructured":"Jack, C. R.Jr. et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer\u2019s disease and amnestic mild cognitive impairment. Brain 131, 665\u2013680 (2008).","journal-title":"Brain"},{"key":"1822_CR36","unstructured":"Therneau, T. M. A package for survival analysis in R. R package version 3.2-7, https:\/\/CRAN.R-project.org\/package=survival (2020)."}],"updated-by":[{"DOI":"10.1038\/s41591-022-02066-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01822-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01822-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T06:08:42Z","timestamp":1665468522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-022-01822-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1038\/s41591-022-01822-2","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41591-022-02066-w","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"3 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-022-02066-w","URL":"https:\/\/doi.org\/10.1038\/s41591-022-02066-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M.M. has served as a consultant for Biogen, Brain Protection Company and Labcorp. J.L.D. was previously an employee and is still a minor shareholder of Eli Lilly and Company. J.L.D. is an inventor on patents or patent applications of Eli Lilly and Company relating to the assays, methods, reagents and\/or compositions of matter used in this work. J.L.D. has also served as a consultant for Karuna Therapeutics and received research support from ADx Neurosciences, Roche Diagnostics and Eli Lilly and Company. R.D.F. and A.A.-S. report no conflicts. D.S.K. serves on a data safety monitoring board for the Dominantly Inherited Alzheimer Network (DIAN) study. D.S.K. also serves on a data safety monitoring board for Biogen but receives no personal compensation. D.S.K. is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals and the University of Southern California. D.S.K. serves as a consultant for Roche, Samus Therapeutics, Third Rock and Alzeca Biosciences but receives no personal compensation. V.J.L. received consulting fees from Bayer Schering Pharma, Piramal Life Sciences and Merck Research, and grants from GE Healthcare, Siemens Molecular Imaging, Avid Radiopharmaceuticals and the NIH. G.B. serves as a consultant for AbbVie, E-Scape and SciNeuro. P.V. received speaking fees from Miller Medical Communications. J.G.-R. receives NIH funding and serves as an assistant editor for <i>Neurology<\/i>. C.R.J. serves on an independent data monitoring board for Roche, has served as a speaker for Eisai and consulted for Biogen but receives no personal compensation from any commercial entity. C.R.J. receives research support from the NIH and the Alexander Family Alzheimer\u2019s Disease Research Professorship of Mayo Clinic. R.C.P. received consulting fees from Hoffman-La Roche, Merck, Genentech, Biogen, GE Healthcare and Eisai.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}